Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma

Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer

(2012) Gabriel A. Rabinovich et al.   IMMUNITY

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

(2012) Bastian von Tresckow et al.   JOURNAL OF CLINICAL ONCOLOGY

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

(2012) Alden A. Moccia et al.   JOURNAL OF CLINICAL ONCOLOGY

Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma

(2012) Diego O. Croci et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders

(2011) J. Ouyang et al.   BLOOD

Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma

(2011) P. Kamper et al.   BLOOD

AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features

(2008) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment

(2008) Eric D. Hsi   LEUKEMIA & LYMPHOMA